Interviews

Exclusive Interview on Drug Stability Testing, Impurity Profiling & Degradation Studies of Pharmaceuticals and ICH guidelines

Key Points of Intellectual Property Rights (IPR) discussed

> IPRs & their importance
> Influence of Intellectual Property Rights in pharmaceutical field
> Global trends in IPRs and harmonization in IPR filing
> Intellectual Property Rights (IPR) as career option
> IPR education institutions and online IPR courses

Summary of the Key Points Discussed in the Interview

• Steps involved in New Drug Development Process ( pharmaceutical product development )
• Cost to develope a new drug and time to take a new drug to come in to the commercial market.

John Earley, Global Head of Lean/Supply System, Astrazeneca, on developing and implementing a global lean program, the best way to conduct a lean transformation, and the challenges of constructing a new supply chain. John Earley is responsible for the development and roll out of an integrated Lean programme throughout AstraZeneca Operations worldwide.

Steve Dreamer is Head of Global Pharma Engineering (GPE) and Head of TechOps Innovation Quality Productivity (IQP). GPE is responsible for providing technical and project management for the major capital investments.

During an interview with India Knowledge@Wharton at the recent Wharton India Economic Forum in Philadelphia, Joshipura discussed these strategies and also the future of pharmaceutical regulation in India, which he believes will copy some of the approaches taken by the U.S. to create a "pharmacovigilance" regime to monitor drug development and new product launches.

Important topics discussed.

About R.S.Prasad :

R.S Prasad is presently Managing Director of Suven Nishtaa Pharma Private Limited, an End to End Pharmaceutical services Providing Organization with the State of the Art Facilities.Since February, 2007 working as Managing Director of Suven Nishtaa Pharma Pvt. Ltd., an associate company of Suven Life Sciences Ltd.

An exclusive interview regarding highlights of 60th IPC, New Delhi.

India's huge potential pharmaceutical market and wealth of industry talent means it will be strategically critical for multinationals in the years ahead, notes Rajiv Gulati, director of India-China strategy and corporate strategic planning for Eli Lilly. But weak intellectual property protection continues to hold the country back by hampering innovation, he says.

Part 2 of an exclusive interview with R.S.Prasad, Managing Director of Suven Nishtaa Pharma Private Limited

You see part 1 here
http://www.pharmainfo.net/interviews/finding-right-solution-secret-my-su...